Trinity Biotech (TRIB) Equity Ratio (2009 - 2025)

Trinity Biotech has disclosed Equity Ratio across 11 years of filings, most recently posting 0.68 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.68, down 100.96% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.68 (down 100.96% YoY), and the FY2025 annual result was 0.68, down 100.96% from the prior year.
• Equity Ratio came in at 0.68 for Q4 2025 at Trinity Biotech, down from 0.34 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.07 in Q3 2022 to a low of 0.68 in Q4 2025.
• The 5-year median for Equity Ratio is 0.18 (2022), against an average of 0.23.
• Across the five-year window, Equity Ratio soared 70.8% in 2021 and tumbled 1605.55% in 2023, its largest moves.
• Trinity Biotech's Equity Ratio stood at 0.0 in 2021, then plunged by 780.55% to 0.02 in 2022, then sank by 1605.55% to 0.4 in 2023, then gained by 15.47% to 0.34 in 2024, then sank by 100.96% to 0.68 in 2025.
• The last three Equity Ratio figures came in at 0.68 (Q4 2025), 0.34 (Q4 2024), and 0.4 (Q4 2023), per Business Quant data.